Updated Charter Redefines Governance of CDC’s Advisory Committee on Immunization Practices

A new charter instructs the CDC’s Advisory Committee on Immunization Practices (ACIP) to evaluate non‑vaccine interventions and modifies the committee’s focus, membership structure, and operating rules.

Leading societies, including the Infectious Diseases Society of America (IDSA), warned that these revisions could jeopardize immunization access and undermine public confidence in U.S. vaccine policy.

The groups stated that the charter unduly highlights perceived gaps or limitations in vaccine data, potentially being used to delay, cancel, or refuse evidence‑based vaccine recommendations.

They added that governance would shift to the CDC director rather than to members with deep immunization expertise, thereby intensifying political influence over the ACIP.

Although the 2024 charter had the CDC’s National Center for Immunization and Respiratory Diseases providing support, the revised charter places ACIP’s support under the CDC Office of the Chief of Staff and other agency components, as directed by the CDC director.

‘This represents a significant governance shift that indicates increased political involvement,’ Richard Hughes IV wrote in an emailed comment. Hughes, lead counsel for the American Academy of Pediatrics’ lawsuit that temporarily blocked HHS Secretary Robert F. Kennedy Jr.’s sweeping changes to ACIP and the childhood immunization schedule, added.

Dorit Reiss, PhD, a law professor at the University of California, San Francisco, noted that the charter no longer mandates three annual meetings; instead, it states that meetings will be scheduled at the discretion of the ACIP Designated Federal Officer, in consultation with the Chair.

Eliminating the three‑meeting requirement makes sessions less predictable, grants HHS and CDC greater discretion over timing, and could slow the pace of vaccine guidance, Hughes cautioned.

Reiss observed that the charter adds four organizations with anti‑vaccine leanings to the liaison representatives, namely the Association of American Physicians and Surgeons, the Independent Medical Alliance, the Medical Academy of Pediatrics and Special Needs, and Physicians for Informed Consent.

The American College of Obstetricians and Gynecologists, which is not among ACIP’s 33 nonvoting liaison organizations and withdrew its liaison status in February, recently issued its own vaccine guidance for pregnant women.

‘That is not good,’ Reiss told MedPage Today.

IDSA and other societies — including the Pediatric Infectious Diseases Society, the Society for Healthcare Epidemiology of America, and the Society of Infectious Diseases Pharmacists — noted that the charter relaxes requirements concerning the publication of vaccine recommendations and their application in insurance coverage decisions.

Hughes added that collectively, these changes indicate that HHS is reshaping ACIP’s structure, membership environment, and operational framework while downplaying the charter’s explicit acknowledgment of the legal implications that underpin its importance.

The charter follows a March ruling by a federal judge finding that Kennedy likely violated federal procedures when he removed all ACIP members last year, replacing them with individuals lacking the required expertise and including vaccine skeptics.

Reiss said the new charter represents an improvement over an April proposal that emphasized potential vaccine harms and was withdrawn by HHS about a month later.

The earlier charter sought to legitimize Kennedy’s panel changes, and the new charter constitutes a retreat from that approach, Reiss noted.

First, the new charter includes a comprehensive, well‑structured section on ACIP’s functions that aligns with the committee’s traditional roles, she noted. It also stresses the importance of transparent, evidence‑based decision‑making and the value of scientific, clinical, and public‑health expertise among panel members, consistent with the committee’s mission.

Finally, it withdraws language from the April version that addressed vaccine adverse events, safety research gaps, cumulative vaccine exposure, component concerns, and mRNA platform issues.

Nevertheless, Hughes cautioned that this does not resolve the underlying legal concerns; it merely revises the paper trail while retaining many of the structural changes.

The charter now calls for panel members to include individuals knowledgeable about consumer perspectives and social or community aspects of immunization programs, whereas the April version permitted expertise in toxicology, pediatric neurodevelopment, and recovery from serious vaccine injuries.

Source link